Tiziana’s nasal foralumab reduces microglial activation in progressive MS trial

Tiziana Life Sciences (TLSA) reported that its nasal foralumab reduced microglial activation in a Phase 2a trial for non-active secondary progressive multiple sclerosis. The 50 microgram dose showed significant reductions on TSPO PET imaging. Both doses improved fatigue, though the study wasn't powered for that endpoint. The company plans to discuss next steps with the FDA.

Original reporting
Published Nov 9, 2026, 7:46 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 9, 2026, 8:02 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Tiziana’s nasal foralumab reduces microglial activation in progressive MS trial — source image
Decision brief

The 30-second read

$TLSABullishHigh
01

Why it matters

The trial met its primary endpoint, showing reduced microglial activation on PET imaging and fatigue improvement, suggesting potential disease‑modifying activity.

02

Market read

First‑time positive data for a microglial‑targeting therapy could drive speculative buying in TLSA and influence the broader neuro‑inflammation sector.

03

What to watch

Small sample size (19 patients) and lack of long‑term safety data could temper enthusiasm.

Relevance 8/10Novelty 8/10Timing: today

Background

Tiziana Life Sciences (NASDAQ:TLSA) announced its first Phase 2a results for nasal foralumab in non‑active secondary progressive multiple sclerosis.

Company-level read

Ticker impact

$TLSABullishHigh confidence
Context

Nasal foralumab Phase 2a trial showed significant reduction in microglial activation and fatigue improvement in progressive MS patients.

Expected impact

upward pressure as market prices in the favorable efficacy signal.

Evidence & confidence

Early‑stage trial success is material for a biotech; the data are new and the company has no approved therapy, so investors will likely bid the stock.

Market effects

May boost sentiment for neuro‑inflammation and MS therapeutic pipelines.

Limited to US biotech investors; no broader regional effect.

Highlights emerging intranasal antibody approaches, of interest to global biotech community.

Counterpoint

Phase 2a data are early; efficacy may not translate to later stages, risk of failure remains high.

Key entities

  • Tiziana Life Sciences Ltd

    Biotech firm developing intranasal foralumab for MS.

  • Ivor Elrifi

    CEO of Tiziana Life Sciences.

Related articles

$TLSAMedAI 8/10

Tiziana Life Sciences Ltd.: Tiziana Life Sciences to Present at the Jefferies Global Healthcare Conference 2026 in London

Tiziana Life Sciences (TLSA) will present at the Jefferies Healthcare Conference in London on November 18, 2026. The company will discuss its Phase 2a INFORM-MS trial results for intranasal foralumab in non-active secondary progressive multiple sclerosis, which met primary endpoints and showed clinical improvements. Management will also be available for one-on-one meetings.

$TLSAHighAI 8/10

Tiziana Life Sciences Ltd.: Tiziana KOL Call Highlights Consistency Between Positive Phase 2a INFORM-MS Topline Results and Longer-Term Clinical Benefits Observed in Expanded Access Program for Patients with Non-Active Secondary Progressive Multiple Scler

Tiziana Life Sciences (TLSA) reported positive Phase 2a INFORM-MS trial results for its lead drug, intranasal foralumab, in treating non-active secondary progressive multiple sclerosis (na-SPMS). Key findings include statistically significant reductions in microglial activation and improvements in fatigue. The results align with longer-term data from the company's expanded access program, showing EDSS stabilization and improvement.

$TLSAHighAI 9/10

A nasal drug for MS reduced a brain inflammation measure in a 12-week trial

Tiziana Life Sciences (TLSA) reported positive Phase 2a trial results for its intranasal foralumab in non-active secondary progressive multiple sclerosis (na-SPMS). The trial met primary endpoints, showing a statistically significant reduction in microglial activation and clinically meaningful fatigue improvements. The company will host a conference call to discuss the results, with key opinion leaders presenting the data. TLSA plans to engage with the FDA for next steps in development.

$TLSAHighAI 8/10

Tiziana's Intranasal Foralumab Meets Primary Endpoints In Phase 2a Multiple Sclerosis Trial

Tiziana Life Sciences (TLSA) reported that its Phase 2a trial of intranasal foralumab met primary endpoints, reducing neuroinflammation and demonstrating safety in non-active secondary progressive multiple sclerosis (na-SPMS) patients. The study showed significant reductions in microglial activation and improvements in fatigue symptoms. TLSA plans to discuss results with the FDA. The stock closed at $0.67 on Monday, up 14.87% in overnight trading.